Characteristic | Number (%) | Median | Range |
---|---|---|---|
Sex | Â | Â | Â |
   Male | 9 (30%) |  |  |
   Female | 21 (70%) |  |  |
Subgroups | Â | Â | Â |
   RF-negative polyarthritis | 11 (37%) |  |  |
   Oligoarthritis extended | 6 (20%) |  |  |
   Oligoarthritis persistent | 13 (43%) |  |  |
   Other subgroups | 0 |  |  |
Age at injection, years | Â | 6.5 | 1-16 |
Disease duration, years | Â | 2.0 | 0.5-13.9 |
Number of joints (n = 40) with | Â | Â | Â |
   Swelling | 38 (95%) |  |  |
   Pain | 35 (88%) |  |  |
   Tenderness at palpation | 39 (98%) |  |  |
   Limited range of motion | 34 (85%) |  |  |
   Active arthritis | 40 (100%) |  |  |
VAS ankle pain patient/parent, cm | Â | 3.5 | 0.2-10.0 |
VAS global assessment patient/parent, cm | Â | 0.6 | 0-9.7 |
VAS global assessment physician, cm | Â | 2.8 | 1-6.8 |
CRP level, mg/l | Â | 2 | 0-22 |
ESR, mm/hour | Â | 14 | 8-69 |
HLA B27 positive, number of patients | 5 (17%) | Â | Â |
ANA positive, number of patients | 14 (47%) | Â | Â |
Second-line drug therapy | Â | Â | Â |
   Methotrexate | 15 (50%) |  |  |
Biologic therapies | Â | Â | Â |
   Etanercept | 3 (10%) |  |  |
   Adalimumab | 2 (7%) |  |  |
   Abatacept | 1 (3%) |  |  |
Systemic corticosteroid therapy | 5 (17%) | Â | Â |